WO1997025426A3 - Compositions and methods for the treatment and diagnosis of breast cancer - Google Patents

Compositions and methods for the treatment and diagnosis of breast cancer Download PDF

Info

Publication number
WO1997025426A3
WO1997025426A3 PCT/US1997/000485 US9700485W WO9725426A3 WO 1997025426 A3 WO1997025426 A3 WO 1997025426A3 US 9700485 W US9700485 W US 9700485W WO 9725426 A3 WO9725426 A3 WO 9725426A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
compositions
treatment
methods
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/000485
Other languages
French (fr)
Other versions
WO1997025426A2 (en
WO1997025426A9 (en
Inventor
Tony N Frudakis Tony Frudakis
John M Smith John M Smith
Steven G Reed Steve G Reed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CORIXA Corp CORIXA CORPORATION
CORIXA CORP CORIXA CORP
Original Assignee
CORIXA Corp CORIXA CORPORATION
CORIXA CORP CORIXA CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CORIXA Corp CORIXA CORPORATION, CORIXA CORP CORIXA CORP filed Critical CORIXA Corp CORIXA CORPORATION
Priority to BR9707125A priority Critical patent/BR9707125A/en
Priority to AU16974/97A priority patent/AU728777B2/en
Priority to JP09525445A priority patent/JP2001501447A/en
Priority to EP97902911A priority patent/EP0874902A2/en
Priority to NZ330887A priority patent/NZ330887A/en
Publication of WO1997025426A2 publication Critical patent/WO1997025426A2/en
Publication of WO1997025426A3 publication Critical patent/WO1997025426A3/en
Publication of WO1997025426A9 publication Critical patent/WO1997025426A9/en
Priority to NO983183A priority patent/NO983183L/en
Anticipated expiration legal-status Critical
Priority to US09/289,198 priority patent/US6586570B1/en
Priority to US09/429,755 priority patent/US6656480B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions and methods for the detection and therapy of breast cancer are disclosed. The compounds provided include nucleotide sequences that are preferentially expressed in breast tumor tissue, as well as polypeptides encoded by such nucleotide sequences. Vaccines and pharmaceutical compositions comprising such compounds are also provided and may be used, for example, for the prevention and treatment of breast cancer. The polypeptides may also be used for the production of antibodies, which are useful for diagnosing and monitoring the progression of breast cancer in a patient.
PCT/US1997/000485 1996-01-11 1997-01-10 Compositions and methods for the treatment and diagnosis of breast cancer Ceased WO1997025426A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BR9707125A BR9707125A (en) 1996-01-11 1997-01-10 Compositions and processes for the treatment and diagnosis of breast cancer
AU16974/97A AU728777B2 (en) 1996-01-11 1997-01-10 Compositions and methods for the treatment and diagnosis of breast cancer
JP09525445A JP2001501447A (en) 1996-01-11 1997-01-10 Compositions and methods for treatment and diagnosis of breast cancer
EP97902911A EP0874902A2 (en) 1996-01-11 1997-01-10 Compositions and methods for the treatment and diagnosis of breast cancer
NZ330887A NZ330887A (en) 1996-01-11 1997-01-10 Monoclonals and polyclonals antibodies for the diagnosis of breast cancer
NO983183A NO983183L (en) 1996-01-11 1998-07-10 Mixtures and Procedures for the Treatment and Diagnosis of Breast Cancer
US09/289,198 US6586570B1 (en) 1996-01-11 1999-04-09 Compositions and methods for the treatment and diagnosis of breast cancer
US09/429,755 US6656480B2 (en) 1996-01-11 1999-10-28 Compositions and methods for the treatment and diagnosis of breast cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58539296A 1996-01-11 1996-01-11
US70001496A 1996-08-20 1996-08-20
US08/585,392 1996-08-20
US08/700,014 1996-08-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US70001496A Continuation-In-Part 1996-01-10 1996-08-20

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US83876297A Continuation-In-Part 1996-01-11 1997-04-09
US83876297A A-371-Of-International 1996-01-11 1997-04-09
US08/991,789 Continuation-In-Part US6225054B1 (en) 1996-01-11 1997-12-11 Compositions and methods for the treatment and diagnosis of breast cancer
US09/598,326 Division US6423496B1 (en) 1996-01-11 2000-06-20 Compositions and methods for the treatment and diagnosis of breast cancer

Publications (3)

Publication Number Publication Date
WO1997025426A2 WO1997025426A2 (en) 1997-07-17
WO1997025426A3 true WO1997025426A3 (en) 1997-10-30
WO1997025426A9 WO1997025426A9 (en) 1997-12-24

Family

ID=27079370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/000485 Ceased WO1997025426A2 (en) 1996-01-11 1997-01-10 Compositions and methods for the treatment and diagnosis of breast cancer

Country Status (10)

Country Link
EP (2) EP0874902A2 (en)
JP (2) JP2001501447A (en)
KR (1) KR19990077146A (en)
CN (1) CN1211279A (en)
AU (1) AU728777B2 (en)
BR (1) BR9707125A (en)
CA (1) CA2242340A1 (en)
NO (1) NO983183L (en)
NZ (1) NZ330887A (en)
WO (1) WO1997025426A2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9315794B2 (en) 2010-07-12 2016-04-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases
US9340780B2 (en) 2010-05-03 2016-05-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
US9347053B2 (en) 2010-05-27 2016-05-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
US9399770B2 (en) 2010-10-06 2016-07-26 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl-tRNA synthetases
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9428743B2 (en) 2010-08-25 2016-08-30 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis
US9580706B2 (en) 2010-04-27 2017-02-28 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
US9593323B2 (en) 2010-05-03 2017-03-14 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
US10564165B2 (en) 2014-09-10 2020-02-18 Genentech, Inc. Identification of immunogenic mutant peptides using genomic, transcriptomic and proteomic information
US10564163B2 (en) 2010-06-11 2020-02-18 Immunovia Ab Method, array and use thereof

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423496B1 (en) 1996-01-11 2002-07-23 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6586570B1 (en) 1996-01-11 2003-07-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6225054B1 (en) 1996-01-11 2001-05-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6656480B2 (en) 1996-01-11 2003-12-02 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6344550B1 (en) 1996-01-11 2002-02-05 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6861506B1 (en) 1996-01-11 2005-03-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US20020068285A1 (en) * 1996-01-11 2002-06-06 Frudakis Tony N. Compositions and methods for the therapy and diagnosis of breast cancer
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
ZA982968B (en) * 1997-04-09 1998-10-27 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
US6379951B1 (en) 1997-12-24 2002-04-30 Corixa Corporation Compounds for immunotherapy of breast cancer and methods for their use
AR014171A1 (en) * 1997-12-24 2001-02-07 Corixa Corp AN ISOLATED POLYPEPTIDE THAT INCLUDES AN IMMUNOGENIC PART OF A PROTEIN OF THE BREAST OR A VARIANT OF SUCH PROTEIN; A MOLECULA OF POLYNUCLEOTIDOS ISOLATED AN EXPRESSION VECTOR; A TRANSFORMED GUEST CELL; A PHARMACEUTICAL COMPOSITION; A VACCINE; A FUSION PROTEIN; A METHOD OF
US6432707B1 (en) 1997-12-24 2002-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6410507B1 (en) 1997-12-24 2002-06-25 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
CA2316397A1 (en) * 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
US6468758B1 (en) 1998-09-23 2002-10-22 Corixa Corporation Compositions and methods for ovarian cancer therapy and diagnosis
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6605432B1 (en) 1999-02-05 2003-08-12 Curators Of The University Of Missouri High-throughput methods for detecting DNA methylation
AU3391200A (en) * 1999-03-04 2000-09-21 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
AU2004218695B2 (en) * 1999-04-09 2008-05-08 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
NZ514646A (en) * 1999-04-09 2005-04-29 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
AU5449600A (en) * 1999-05-28 2000-12-18 Corixa Corporation Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
AU7573000A (en) * 1999-09-01 2001-03-26 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
WO2001040269A2 (en) 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
EP1672070A3 (en) * 1999-12-01 2006-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003527104A (en) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド IL-17 homologous polypeptides and their therapeutic uses
EP1487877B1 (en) * 2001-09-18 2010-10-27 Genentech, Inc. Compositions and methods for the diagnosis of tumors
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
CN1898563B (en) * 2003-09-24 2011-11-23 肿瘤疗法科学股份有限公司 Ways to Diagnose Breast Cancer
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
JP2006238757A (en) * 2005-03-02 2006-09-14 Eiken Chem Co Ltd Markers for detecting cancer
KR100689274B1 (en) * 2005-03-30 2007-03-08 김현기 Human primary cancer gene, protein encoded thereby
SG10201608871XA (en) 2008-05-05 2016-12-29 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
CA2759848C (en) 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CN103140233B (en) 2010-05-03 2017-04-05 Atyr 医药公司 Treatment, diagnosis and the discovery of antibody compositions related to the protein fragments of methionyl-tRNA synthetase
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
JP6008844B2 (en) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of the p38 MULTI-tRNA synthetase complex
US9062301B2 (en) 2010-05-04 2015-06-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CN103096914B (en) 2010-05-17 2015-08-12 Atyr医药公司 Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of leucyl-tRNA synthetase
EP2575857B1 (en) 2010-06-01 2018-01-24 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
EP2593125B1 (en) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
US9816084B2 (en) 2011-12-06 2017-11-14 Atyr Pharma, Inc. Aspartyl-tRNA synthetases
US9822353B2 (en) 2011-12-06 2017-11-21 Atyr Pharma, Inc. PEGylated aspartyl-tRNA synthetase polypeptides
WO2013115926A2 (en) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
WO2014075788A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
CN110536694A (en) 2017-04-20 2019-12-03 Atyr 医药公司 Compositions and methods for treating pulmonary inflammation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002062A2 (en) * 1989-08-04 1991-02-21 Triton Biosciences, Inc. C-erbb-2 external domain: gp75
GB2273099A (en) * 1992-11-10 1994-06-08 Asta Medica Ag Glycoprotein encoded by a human endogenous retrovirus K envelope gene
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
WO1995032311A1 (en) * 1994-05-23 1995-11-30 Calypte, Inc. Non-hiv antibodies as disease markers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002062A2 (en) * 1989-08-04 1991-02-21 Triton Biosciences, Inc. C-erbb-2 external domain: gp75
GB2273099A (en) * 1992-11-10 1994-06-08 Asta Medica Ag Glycoprotein encoded by a human endogenous retrovirus K envelope gene
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
WO1995032311A1 (en) * 1994-05-23 1995-11-30 Calypte, Inc. Non-hiv antibodies as disease markers

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BYRNE J A ET AL: "A SCREENING METHOD TO IDENTIFY GENE COMMONLY OVEREXPRESSED IN CARCINOMAS AND THE IDENTIFICATION OF A NOVEL COMPLEMENTARY DNA SEQUENCE", CANCER RESEARCH, vol. 55, no. 13, 1 July 1995 (1995-07-01), pages 2896 - 2903, XP002025781 *
HALTMEIER M ET AL: "Identification of S71-related human endogenous retroviral sequences with full-length pol genes.", VIROLOGY, JUN 1 1995, 209 (2) P550-60, UNITED STATES, XP002031074 *
LEIBMOSCH C ET AL: "EVOLUTION AND BIOLOGICAL SIGNIFICANCE OF HUMAN RETROELEMENTS", VIRUS GENES, 1995, 11, 133-145, XP000673508 *
WATSON M A ET AL: "ISOLATION OF DIFFERENTIALLY EXPRESSED SEQUENCE TAGS FROM HUMAN BREAST CANCER", CANCER RESEARCH, vol. 54, no. 17, 1 September 1994 (1994-09-01), pages 4598 - 4602, XP000576043 *
WERNER T ET AL: "S71 is a phylogenetically distinct human endogenous retroviral element with structural and sequence homology to simian sarcoma virus (SSV).", VIROLOGY, JAN 1990, 174 (1) P225-38, UNITED STATES, XP000670325 *
ZEHAN CHEN ET AL: "DIFFERENTIAL EXPRESSION OF HUMAN TISSUE FACTOR IN NORMAL MAMMARY EPITHELIAL CELLS AND IN CARCINOMAS", MOLECULAR MEDICINE, vol. 1, no. 2, January 1995 (1995-01-01), pages 153 - 160, XP000607858 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499609B2 (en) 2005-11-24 2016-11-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9580706B2 (en) 2010-04-27 2017-02-28 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases
US9593323B2 (en) 2010-05-03 2017-03-14 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
US9340780B2 (en) 2010-05-03 2016-05-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
US9347053B2 (en) 2010-05-27 2016-05-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
US10564163B2 (en) 2010-06-11 2020-02-18 Immunovia Ab Method, array and use thereof
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9315794B2 (en) 2010-07-12 2016-04-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases
US9428743B2 (en) 2010-08-25 2016-08-30 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
US9399770B2 (en) 2010-10-06 2016-07-26 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl-tRNA synthetases
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
US10564165B2 (en) 2014-09-10 2020-02-18 Genentech, Inc. Identification of immunogenic mutant peptides using genomic, transcriptomic and proteomic information
US12372533B2 (en) 2014-09-10 2025-07-29 Genentech, Inc. Identification of immunogenic mutant peptides using genomic, transcriptomic and proteomic information

Also Published As

Publication number Publication date
EP1876241A3 (en) 2008-07-30
WO1997025426A2 (en) 1997-07-17
AU1697497A (en) 1997-08-01
JP2008043337A (en) 2008-02-28
NO983183L (en) 1998-09-10
EP0874902A2 (en) 1998-11-04
CN1211279A (en) 1999-03-17
EP1876241A2 (en) 2008-01-09
CA2242340A1 (en) 1997-07-17
BR9707125A (en) 1999-07-20
AU728777B2 (en) 2001-01-18
KR19990077146A (en) 1999-10-25
JP2001501447A (en) 2001-02-06
NZ330887A (en) 2001-01-26

Similar Documents

Publication Publication Date Title
WO1997025426A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2000061612A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
HUP0203035A2 (en) Compositions and methods for therapy and diagnosis of prostate cancer
EP2022800A3 (en) Compositions for the therapy and diagnosis of ovarian cancer
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO2000055180A3 (en) Human lung cancer associated gene sequences and polypeptides
WO2000036107A3 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
WO2000052165A3 (en) Compositions and methods for breast cancer therapy and diagnosis
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO2000061753A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
ATE514780T1 (en) COMPOSITIONS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER AND USE THEREOF
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO1999037775A3 (en) Compositions and methods for detecting and treating breast cancer
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2004005349A3 (en) Preparation based on an antibody directed against a tumor-associated glycosylation such as lewis structures
WO1999054466A3 (en) Colon cancer-associated antigens and their diagnostic and therapeutic uses
WO2002045657A3 (en) Ovarian tumor antigen and methods of use therefor
WO2001055391A3 (en) 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
DE60139150D1 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
AU2002365104A8 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97192251.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT.BUL.31/97 UNDER INID (30) "PRIORITY DATA", REPLACE "960110" BY "960111"

COP Corrected version of pamphlet

Free format text: PAGES 3/21-6/21 AND 8/21-20/21,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 330887

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2242340

Country of ref document: CA

Ref document number: 2242340

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1997 525445

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/005611

Country of ref document: MX

Ref document number: 1019980705283

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1997902911

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997902911

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019980705283

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019980705283

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997902911

Country of ref document: EP